All In Biotech

Drug Trial Radar · NCT07862569

DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Doravirine/Islatravir (100 mg/0.25 mg) in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 23, 2026

Primary completion

Sep 24, 2029

Study completion Dec 23, 2033

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) \[MK-8591A\] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive. The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.

Conditions

  • HIV-1
  • HIV Infection

Interventions

  • DOR/ISLDrug

    DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISLTime frame: At designated timepoints on Day 28
  2. Maximum plasma concentration (Cmax) of ISLTime frame: At designated timepoints on Day 28
  3. Time to maximum plasma concentration (Tmax) of ISLTime frame: At designated timepoints on Day 28
  4. Apparent plasma terminal half-life (t½) of ISLTime frame: At designated timepoints on Day 28
  5. Apparent clearance (CL/F) of ISLTime frame: At designated timepoints on Day 28
  6. Volume of distribution (Vz/F) of ISLTime frame: At designated timepoints on Day 28
  7. Percentage of participants with ≥1 adverse event (AE) through Week 24Time frame: Up to ~24 weeks
  8. Percentage of participants discontinuing from study therapy due to AE(s) through Week 24Time frame: Up to ~24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Florida ( Site 1505)

    Tampa, Florida

  • The Children's Hospital at Montefiore ( Site 1507)

    The Bronx, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.